Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Active:	Yes
Cancer Type:	Gynecologic Cancers Ovarian Cancer Primary Peritoneal Cancer	NCT ID:	NCT06276491
Trial Phases:	Phase I	Protocol IDs:	XmAb541-01 (primary) NCI-2024-03773
Eligibility:	15 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Xencor, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06276491

Summary

The primary purpose of this study is to determine whether the investigational drug
XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for
further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.